Kimberly-Clark closes Kenvue acquisition, sets $3.1 billion integration program

What happened

Kimberly-Clark Corporation, the Dallas-based maker of consumer paper products such as Kleenex, Scott and Huggies, completed its previously announced acquisition of Kenvue Inc. on November 2, 2026, according to a Form 8-K filed the same day. Kenvue is the consumer health company spun off from Johnson & Johnson in 2023, whose brands include Tylenol, Band-Aid and Neutrogena.

Under the merger agreement signed November 2, 2025, each outstanding share of Kenvue common stock was converted into the right to receive 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash, without interest. Kimberly-Clark said it delivered or is obligated to deliver approximately 281,060,840 shares of its common stock in the aggregate. Holders entitled to fractional shares will receive cash instead.

The deal was structured as two back-to-back mergers: a Kimberly-Clark subsidiary merged into Kenvue, which became a wholly owned Kimberly-Clark subsidiary, and that company then merged into a second subsidiary, which survived and was renamed Kenvue LLC.

Kimberly-Clark's board also approved the Kenvue Integration Program on October 30, 2026. The company said the program is intended to achieve operating profit synergies by 2030, with actions starting November 2, 2026 and expected to be completed by December 31, 2029. Kimberly-Clark estimates cumulative pre-tax charges of about $3.1 billion over that period — $2.5 billion in cash and $0.6 billion non-cash — plus about $1.4 billion of capital spending.

The cash charges break down as roughly $0.8 billion for supply chain network optimization, $0.6 billion for enterprise resource planning and technology integration, $0.4 billion for workforce optimization, $0.4 billion for advisory services, and $0.3 billion for program management and other restructuring and integration costs. The company said the estimates rest on assumptions and that actual results may differ.

Kimberly-Clark also disclosed board changes. Three Kenvue directors — Richard E. Allison, Jr., Larry J. Merlo and Kirk L. Perry — joined Kimberly-Clark's board at closing and will be nominated for election at the 2027 annual meeting. Allison joined the audit committee; Merlo joined the management development and compensation and nominating and corporate governance committees. Directors Mae C. Jemison, Christa S. Quarles and Jaime Ramirez resigned at closing; the filing states the resignations were solely to create vacancies for the Kenvue designees and were not the result of any disagreement with the company.

The board amended the company's 2021 Equity Participation Plan to allow shares from an acquired company's pre-existing stockholder-approved plan to be used for awards, and adopted bylaw amendments that revise advance notice and disclosure requirements for stockholder proposals and director nominations, effective at closing.

Kimberly-Clark also granted one-time, premium-priced stock options to executives effective December 1, 2026, conditioned on completing the Kenvue deal. Chief Executive Michael Hsu received a grant valued at $6.6 million, Chief Financial Officer Nelson Urdaneta $2.15 million, and Chief Strategy Officer Jeffrey Melucci $1.8 million. The exercise price will be the greater of $120.00 or 110% of the closing price on the grant date, and the options vest in full on December 1, 2029.

The market response

Kimberly-Clark shares closed at $108.79 on the event date, up 4.15% from the prior close of $104.46, according to the price data. Volume was about 14.5 million shares, roughly 3.17 times the average volume of about 4.58 million. The filing does not discuss the share price reaction.

What this means

A Form 8-K is a current report that a US public company must file with the Securities and Exchange Commission to disclose material events between quarterly reports. The numbered items on the form indicate which categories apply. Item 2.01 covers the completion of a significant acquisition, which is what this filing reports. Item 2.05 covers costs associated with exiting or disposing of activities — here, the restructuring charges planned for the integration. Item 5.02 covers changes to directors and certain officers. Item 5.03 covers amendments to bylaws or charter. Item 7.01 is a voluntary disclosure channel, and Item 9.01 attaches exhibits such as the merger agreement.

The consideration has two parts. The 0.14625 exchange ratio is the number of Kimberly-Clark shares each Kenvue share converts into — a stock-for-stock structure that gives Kenvue holders a stake in the combined company. The $3.50 cash portion is separate, paid per Kenvue share. Together they form the merger consideration, and the split between stock and cash determines how much of the deal is funded with new Kimberly-Clark shares rather than cash on hand or debt. The roughly 281 million new shares represent dilution of existing Kimberly-Clark holders' ownership, which is why the exact exchange ratio matters to investors.

The equity awards described are stock options — the right, not the obligation, to buy shares at a set price within a set period. These are 'premium-priced,' meaning the exercise price will be at least $120.00, or 110% of the stock's closing price on the grant date if that is higher. The grant value of $6.6 million for the CEO is not the number of shares or the amount of cash; it is the value the company assigned to the option grant, which is then converted into a share count using a Black-Scholes valuation, a standard option-pricing model. The options vest in full on December 1, 2029, meaning the executive must generally stay employed until then to exercise them.

The integration program's $3.1 billion in expected charges is not a payment made at closing. It is an estimate of costs Kimberly-Clark expects to record over the next three years as it combines the two businesses: closing or reshaping factories, merging computer systems, cutting staff, and paying advisers. The cash portion of roughly $2.5 billion is money that will actually leave the company; the $0.6 billion non-cash portion is primarily accounting charges such as asset write-downs. The separate $1.4 billion of planned capital spending is money invested in facilities and systems, not an expense. Because the total is an estimate, the company explicitly warned that actual results may differ.

Kenvue is now a wholly owned subsidiary of Kimberly-Clark, so Kenvue shares no longer trade independently and holders receive Kimberly-Clark shares and cash in exchange. The three Kenvue directors joining the board reflect the merger agreement's governance terms, and the resignations were arranged to make room for them. The 2027 nomination commitment means shareholders will get a vote on those directors at that annual meeting.